NewsRoom Articles - Page 130 of 230

TuesdayMay 10, 2022 3:09 pm

Study Finds Service Dogs Help Individuals with PTSD

Post-traumatic stress disorder is a mental health disorder brought on by experiencing or witnessing a traumatic or terrifying event. This condition may last a few months or even years, with triggers unearthing traumatic memories and causing intense physical and emotional reactions. To help manage the condition’s symptoms, patients are sometimes assigned a buddy dog to be their companion during their daily activities. For a long time, patients with post-traumatic stress disorder have argued that a buddy dog helped better their lives. However the lack of scientific evidence made it hard to substantiate these claims — until now. A new study…

MondayMay 09, 2022 2:02 pm

U.S. Army Sued Over Discharging Soldiers with Substance-Abuse Issues

The U.S. Army is being sued for violating the Constitution as well as its own regulations and veterans’ rights by failing to give soldiers with drug and alcohol use disorders honorable discharges, which would have qualified them for federal benefits. Army Secretary Christine Wormuth is being sued by Mark Stevenson, an army veteran, in federal court. Stevenson seeks to compel the military to upgrade his discharge status as well as those of other veterans who weren’t honorably discharged due to misconduct associated with their substance abuse disorders. Stevenson enlisted in the U.S. Army in 1977, revealing that he developed problems…

FridayMay 06, 2022 11:54 am

Study Finds Strong Link Between Hormone Drug, Growth of Brain Tumors

A new study has found that a drug that is commonly used to hormonally treat conditions such as prostate cancer, early puberty and excessive hair growth may be linked to a heightened risk of meningioma. The study was carried out by researchers at the University of Bristol who collaborated with researchers at the National University of Singapore and the University of Cambridge. The findings were published in “Scientific Reports.” Meningioma is a common type of brain tumor that is typically benign and slow growing. These tumors are known to trigger disability by squeezing or compressing the adjacent vessels and nerves…

FridayMay 06, 2022 9:00 am

Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial

Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward in the study of alternative treatments for major depressive disorder, Cybin (NEO: CYBN) (NYSE American: CYBN) is moving forward in its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003 (https://ibn.fm/VTjoI). Based on previous research, CYB003 has the potential to effectively treat MDD with significant…

ThursdayMay 05, 2022 12:52 pm

New Study Sheds Light on Inflammation Linked to COVID-19

A new study has provided new insights into why the SARS-CoV-2 virus, which is known to cause COVID-19, can sometimes fuels inflammation, which in turn causes serious illness. This research was led by scientists at Boston Children’s Hospital and Harvard Medical School. Its findings were published in the “Nature” journal. The researchers also discovered that the SARS-CoV-2 virus infects and kills specific cells in the immune system in the lungs and the blood. The elimination of these alarms is what triggers the immune system. In a news release, Professor Judith Lieberman, one of the leaders of the study, stated that…

WednesdayMay 04, 2022 3:17 pm

Study Says Antidepressants Don’t Meaningfully Improve Depressed People’s Well-Being

Depression is a mood disorder that causes an individual to experience feelings of sadness that persist for longer than a fortnight, which impacts their ability to carry out daily activities. A recently conducted study has found that individuals who use antidepressants to manage their depression observe no improvements in their overall mental and physical well-being in comparison to those who don’t take antidepressants. Figures from the National Institute of Mental Health show that more than 20 million grownups in America have suffered at least one depressive episode in the course of their lives. The study’s findings were published in “PLOS…

TuesdayMay 03, 2022 3:07 pm

Johns Hopkins Researchers Receive Millions for New Cancer Research Projects

The Departments of Pathology, Neurosurgery and Gynecology/Obstetrics and the Kimmel Cancer Center at Johns Hopkins have received almost $8 million for new research projects to discover cures for a number of fatal cancers, including ovarian cancer, pancreatic cancer and glioblastoma. The projects are being financed by Break Through Cancer, a cancer research foundation, as part of an effort for researchers across a quintet of cancer research centers. The other cancer research centers include the University of Texas MD Anderson Cancer Center in Houston; Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts; the Memorial Sloan Kettering Cancer Center in…

MondayMay 02, 2022 1:59 pm

Researchers May Have Found New Way to Slow Progression of Cancer

Scientists at the University of Sussex may have discovered a way to decrease the speed at which glioblastoma grows and strengthen potential treatments for the brain tumor. Glioblastoma is a common tumor found in adults. This aggressive tumor is often resistant to treatment, making it fatal. In their new study, researchers have shown that differentiation therapy may be used to limit the growth of the tumors and turn off the malignant properties of cancerous cells. They suggest that an inhibitor drug known to target certain cell proteins may be used to make glioblastoma treatments more effective. Professor Georgios Giamas of…

FridayApr 29, 2022 12:31 pm

Research Highlights the High Economic Cost of PTSD

New research has found that the national economic burden of post-traumatic stress disorder (“PTSD”) exceeds the costs of other mental disorders such as depression and anxiety. Researchers estimate the cost of post-traumatic stress disorder for 2018 to be roughly $232 billion. They highlighted the need for more effective therapies, to increase awareness of post-traumatic stress disorder, and for the expansion of new strategies to decrease the economic and clinical burden of mental health disorders. The researchers stated that the PTSD economic burden in America shown in the study was “astonishing” and highlighted the urgency for private and public stakeholders to…

ThursdayApr 28, 2022 1:54 pm

Colorado Patients Reap Benefits of Ketamine Treatments for Depression

Patients with severe depression in the state of Colorado who haven’t been successful in managing their indication with antidepressants have turned to ketamine. Ketamine is a prescription drug used by veterinarians and medical practitioners as an anesthetic. Researchers at Yale have found that this drug prompts the brain to make new neural connections, allowing it to form more positive behaviors and thoughts. A new community health program, the Mental Health Center of Denver, has been providing ketamine therapy. It is currently the only clinic in the state offering this particular therapy and is among the few in the country servicing…